RT Journal Article
SR Electronic
T1 Multi-omic landscaping of human midbrains identifies neuroinflammation as major disease mechanism in advanced-stage Parkinson’s disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.08.21258527
DO 10.1101/2021.06.08.21258527
A1 Gomes, Lucas Caldi
A1 Galhoz, Ana
A1 Jain, Gaurav
A1 Roser, Anna-Elisa
A1 Maass, Fabian
A1 Carboni, Eleonora
A1 Barski, Elisabeth
A1 Lenz, Christof
A1 Lohmann, Katja
A1 Klein, Christine
A1 Bähr, Mathias
A1 Fischer, André
A1 Menden, Michael P.
A1 Lingor, Paul
YR 2021
UL http://medrxiv.org/content/early/2021/06/12/2021.06.08.21258527.abstract
AB Parkinson’s disease (PD) is the second most common neurodegenerative disorder whose prevalence is rapidly increasing worldwide. The disease mechanisms of sporadic PD are not yet completely understood. Therefore, causative therapies are still lacking. To obtain a more integrative view of disease-mediated alterations, we investigated the molecular landscape of PD in human post-mortem midbrains. Tissue from 13 PD patients and 10 controls was subjected to small RNA sequencing, transcriptomics, and proteomics analysis. Differential expression analyses were performed reveal multiple deregulated molecular targets linked to known pathomechanisms of PD as well as novel processes. We found significant differential expression of miR-539-3p, miR-376a-5p, miR-218-5p, and miR-369-3p, the valid miRNA-mRNA interacting pairs of miR-218-5p/RAB6C, and miR-369-3p/GTF2H3, as well as multiple proteins relevant in the pathology of PD, including CHI3L1, SELENBP1, PRDX1, HSPA1B, and TH. Vertical integration of multiple omics analyses allowed to validate disease-mediated molecular alterations across different molecular layers and functional annotation of differentially expressed targets identified a strong enrichment of pathways related to inflammation and activation of the immune response. This suggests that neuroinflammation may significantly contribute to disease progression in PD and may be a promising therapeutic target in advanced stages of PD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Cluster of Excellence and DFG Research Center Nanoscale Microscopy and Molecular Physiology of the Brain, Goettingen, Germany (PL), and by Bridging Funds from the Goettingen Graduate Center for Neurosciences, Biophysics, and Molecular Biosciences (LCG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human midbrain samples were provided by the Parkinson's UK Brain Bank (Imperial College London, London, England). The samples were conceded to the Lingor Lab (Department of Neurology, University Medical Center Goettingen, Goettingen, Germany). Ethical approval was given by the Multicenter Research Ethics Committee (07/MRE09/72).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRNA sequencing and proteomics datasets were deposited in public repositories (the European Genome-phenome Archive (EGA) and the Proteomics Identifications Database (PRIDE), respectively) following applicable guidelines. RNA sequencing data are stored under the accession number EGAD00001006883. Proteomics data are available via ProteomeXchange with the identifier PXD023618.CTRcontrolPDParkinson’s diseasePMIpostmortem intervalAgeage at deathNP diagnosisneuropathological diagnosisGenderF-females/M-malesLBDBSLewy body disease brainstem variantLBDELewy body disease early-neocortical stageLBDNLewy body disease neocortical stagemiRNAmicroRNAGOGene OntologyBPbiological processCCcellular compartmentKEGGKyoto Encyclopedia of Genes and GenomesFDRfalse discovery rateDEdifferentially expressedFCfold changepiRNAPiwi-interacting RNArRNAribosomal RNAsnoRNAsmall nucleolar RNAsncRNAsmall non-coding RNA